Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 37,500 shares, a growth of 24.6% from the January 31st total of 30,100 shares. Based on an average trading volume of 20,836,400 shares, the days-to-cover ratio is currently 0.0 days.
Q BioMed Price Performance
Shares of QBIO stock remained flat at $0.01 during trading hours on Friday. 401,719 shares of the stock were exchanged, compared to its average volume of 6,706,117. The business has a 50 day moving average of $0.01 and a two-hundred day moving average of $0.02. Q BioMed has a 52-week low of $0.00 and a 52-week high of $0.47.
Get
Q BioMed alerts:
About Q BioMed
(Get Rating)
Q BioMed, Inc operates as a biomedical acceleration and development company. It focuses on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Its products include Strontium-89, MetastronTM, QBM-001, Uttroside-B, and MAN 01. The company was founded by Enrique Navas on November 22, 2013 and is headquartered in New York, NY.
Read More
- Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
Q BioMed Inc.(场外交易代码：QBIO-GET Rating)是2月份空头股数显著增长的接受者。截至2月15日，空头股数共有37,500股，比1月31日的30,100股增长了24.6%。以平均成交量20,836,400股计算，目前天数与回补比率为0.0天。
Q BioMed性价比
在周五的交易时段，QBIO股票的股价持平于0.01美元。该股成交量为401,719股，而平均成交量为6,706,117股。该业务的50日移动均线切入位在0.01美元，200日移动均线切入位在0.02美元。Q BioMed的52周低点为0.00美元，52周高位为0.47美元。
到达
Q BioMed警报：
关于Q BioMed
(获取评级)
Q BioMed，Inc.是一家生物医学加速和开发公司。它的重点是获得和许可临床前、临床阶段和批准的生命科学治疗产品。其产品包括锶-89、MetstronTM、QBM-001、Uttroside-B和MAN 01。该公司由恩里克·纳瓦斯于2013年11月22日创立，总部设在纽约州纽约。
阅读更多内容
- 免费获取有关Q BioMed(QBIO)的StockNews.com研究报告
- 市场回顾周-2/27-3/3
- 升幅最大的3只股票正在逆转
- 如何寻找蓝筹股分红股
- Zscaler，Inc.Plummets，是时候去抄底了吗？
- 什么是好的股息收益率？如何决定
接受Q BioMed Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Q BioMed和相关公司的最新新闻和分析师评级的每日简要摘要。
